



Recommendations for the submission of poster abstracts

We recommend that you follow the instructions below to prepare your abstract. If you find problems during your submission or if you have any questions, do not hesitate to send an email to: lmcdiabete@gmail.com

GENERAL CONSIDERATIONS

- Submission of poster abstracts is exclusively electronic and must be done on the website of the **Moroccan League for the Fight against Diabetes** (www.lmcd.com) within the indicated deadlines. **No submission by mail, fax or email will be accepted.**
- The summary should be structured (see below). **It must be less than 3000 characters.**
- If you wish to modify your submission, please send an email specifying: the title, the name of the first author, the date of submission and the desired modifications to: lmcdiabete@gmail.com
- The Scientific Committee reserves the right to refuse abstracts that do not meet the formal criteria.
- **English or French language can be used.**

THE SUMMARY

- Abstracts may include original work, original clinical cases, and reviews.
- Abstracts should be structured in [Introduction, Materials and Methods, Results, Conclusion.](#)
- An **original work** asks a question (introduction), describes the means used to answer it (material and method), gives the results and the conclusions. The conclusion must relate only to the question asked.
- The **Clinical cases** must report original or exceptional observations. The observation (or observations) must be put in the box material and method.
- A **review** discusses a limited subject from recent publications and the personal

experience of the authors. You must avoid the simple juxtaposition of contradictory results. We are waiting for an explanation of the contradictions, your personal opinion and suggestions for resolving the controversial points.

- It is not possible to integrate images, tables or references to abstracts.
- **An unstructured summary may result in rejection of the submission.**

ABBREVIATION AND UNITS

Abbreviations should only be used if the word has already been quoted at least once. For chemical names, long therapeutic associations and diagnostic tests better known by their abbreviation. The units are to be presented according to international recommendations. The generic name of the drug is to be used first, followed by the trade name in parentheses, accompanied by the symbol ®.

VALIDITY

We remind you that the author agrees that the summary, once accepted, will be presented, and it will no longer be possible to withdraw or request its removal.

CONFIDENTIALITY

The scientific committee, the organizing committee and any legal person having access to the submitted data undertake not to divulge or exchange any information contained in the abstracts with a third party before their official presentation.

Please note that **April 30, 2021** is the last deadline
to submit your poster abstracts.

Submit your poster abstract